Physician profile
Fred Bayon
NPI 1225031362
$18,329.94
in general payments reported to CMS, 2019-2025
51 companies · $2,084 in 2025
The $2,084 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,232 · 2020: $2,767 · 2021: $2,767 · 2022: $2,773 · 2023: $2,411 · 2024: $2,297 · 2025: $2,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,760 · Education: $31.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,759.75 |
| Education | $31.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,054.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,907.76 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $1,810.04 | 2019-2022 | |
| Abbvie INC. | $1,653.98 | 2019-2025 | Qulipta, Vraylar, Linzess |
| Pfizer INC. | $1,512.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,313.94 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,246.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,244.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $682.41 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $592.39 | 2020-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $540.17 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceutical Holding Company Ltd. | $421.37 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $394.96 | 2021 | |
| Allergan, INC. | $340.58 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $328.25 | 2022-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Bayon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.